The efficacy and adverse reactions of different infusion plan of zoledronic acid in patients with osteoporosis

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038593

Enrollment

Unknown

Registered

2020-09-24

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

1:infuse zoledronic acid 100% in one time

2: infuse 20% of zoledronic acid for the first time,infuse the other 80% for the second time

3:infuse 50% of zoledronic acid for the first time,infuse the other 50% for the second time

4:infuse 80% of zoledronic acid for the first time,infuse the other 20% for the second time

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients diagnosed with primary osteoporosis

Exclusion criteria

Exclusion criteria: 1) Patients with renal insufficiency (creatinine clearance rate <35ml/min); 2) Patients using steroids, non-steroidal anti-inflammatory drugs or other drugs that may affect drug efficacy and inflammatory indicators; 3) Patients with muscle and connective tissue diseases with fever, muscle soreness and other symptoms; 4) Patients with local or systemic infectious diseases; 5) Patients with secondary osteoporosis.

Design outcomes

Primary

Measure	Time frame
IL-6;TNF-alpha;CRP;DXA;blood calcium;Creatinine clearance rate;parathyroid hormone;ALP;25-OH-VD;calcitonin;PINP;ß-Crosslaps;N-MID;	—

Countries

China

Contacts

Public ContactYin Liangjun

Department of Orthopaedics, the Second Affiliated Hospital of Chongqing Medical University

albertyin.21@163.com+86 13594668983

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026